Mantle cell lymphoma (MCL), typically CD5 þ , CD23À B cells, is a particularly difficult type of non-Hodgkin's lymphoma (NHL) in that it behaves aggressively but is incurable with standard therapy. 1 New therapies are clearly needed. Thus, it would be very useful to have an animal model for MCL.
Mantle cell lymphoma is characterized by the chromosome translocation t(11;14), which dysregulates expression of the cyclin D1 gene. It seemed reasonable that transgenic mice carrying Em-cyclinD1 should develop MCL. Surprisingly, however, such mice developed normally and failed to develop tumors. 2 B-lymphocyte development appeared normal. Crossing of Em-cyclinD1 transgenic mice with c-myc transgenic mice led to accelerated development of an aggressive lymphoma of the type seen with c-myc alone, but not MCL, 2 and c-myc is not commonly rearranged in MCL. Thus, cyclin D1 appears to be necessary, but not sufficient, for mantle cell lymphomagenesis.
Therefore, additional genetic events are necessary for the development of MCL.
The model of plasmacytomas occurring in certain mouse strains injected with the isoprenoid alkane pristane (2,6,10,14-tetramethylpentadecane) may be an example of the effect of mitogenic stimulation on disease development. Pristane injections have been found to induce IgA secreting plasmacytomas in susceptible mouse strains, in particular BALB/c, but not in most other strains, including C57/BL6, following approximately a 1 year latency period. 3 Since MCL, like plasmacytoma, is a B-cell lymphoproliferative disorder, we hypothesized that mitogenic stimulation of B cells might act as a more general promoter of development of MCL in B cells with an underlying aberrant expression of cyclin D1. That is, mitogenic stimulation of B cells to enhance the opportunity for occurrence of random genetic alterations followed by in vivo selection of cells with a growth advantage might promote development of a lymphoma with characteristics of MCL in cyclin D1 expressing B cells.
Bcl-1 (Em-cyclin D1) transgenic mice were obtained (courtesy of Dr Alan Harris) and bred in the Fox Chase Laboratory Animal Kaplan-Meier plot was significant in distinguishing the considered clusters (P ¼ 0.0179).
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Facility (LAF) under an approved IACUC protocol. We used intraperitoneal (i.p.) injection of 0.5 cc pristane (Sigma, St. Louis, MO) monthly for 3 months, the same dose and schedule used to induce plasmacytomas. 4 Tumors were characterized by routine histology after hematoxylin-eosin staining and immunohistochemistry for cyclin D1 or CD20. Ascites or single-cell suspensions of spleen were characterized by flow cytometric immunophenotyping for the B-cell marker B220 (CD45), CD19, CD23 and CD5.
In a pilot experiment, we injected four Em-cyclin D1 transgenic mice and two non-transgenic littermates, all more than 1-year-old, with 0.5 cc pristane i.p. monthly for 3 doses, a dose and schedule described for plasmacytoma development. When we repeated our experiments using younger mice, no lymphomas developed in three separate experiments. We repeated the pristane injections in mice of various ages and confirmed an age-dependence for lymphoma development. None of 17 mice injected when they were between 1 and 9 months of age (4 at 1-2 months, 10 at 5-7 months and 2 at 8-9 months) developed lymphoma, even when observed for their entire natural lifespan. Four of six mice injected with pristane when they were 10-11 months old, and all nine mice injected beginning between 12 and 14 months of age, overall 13/15 (Po0.001; w 2 ), developed B-cell lymphoma within 1 month of the third injection. Older (12-14 months) non-transgenic littermates did not develop lymphoma following pristane injections. Thus, events that occur with aging enhance the Letters to the Editor susceptibility of cyclin D1, but not of non-transgenic littermates, to pristane-induced lymphoma.
We have also directly investigated a 'two-hit' model for lymphomagenesis. As mantle cells express bcl-2, and it seemed logical that a proliferation gene, bcl-1/cyclinD1, and an antiapoptotic gene, bcl-2, might have cooperative effects, we crossbred Em-cyclin D1 X Em-bcl2 mice. None of more than 50 double-transgenic mice developed lymphoma.
As lymphoma susceptibility is strain-specific, we crossed the Em-cyclin D1 transgenic mice, which are in C57BL6 background, with wild-type BALB/c mice for nine generations and no spontaneous lymphomas occurred in the Em-cyclin D1/BALBc mice.
The histology of this lymphoma model and its characterization as CD5 þ , CD23À, cyclin D1 þ monoclonal IgM þ B cells indicate that pristane injection of older Em-cyclin D1 transgenic mice recapitulates human MCL. Thus, we have developed a murine model of MCL that relies on at least three distinct stages of lymphomagenesis. The mice must have the initiating event of dysregulated cyclin D1 expression, here due to the Em-cyclin D1 transgene. They must then undergo changes associated with aging that may sensitize the cells to the effects of pristane. This indicates age dependence for developing lymphoma, reminiscent of the increased incidence of lymphoma in humans with aging. Finally, pristane injections are required for the ultimate progression to lymphoma. This may act as a nonspecific mitogenic stimulus that permits additional genetic alterations to occur in dividing B lymphocytes or as an immune stimulant leading to cytokine release (as with IL-6 for plasmacytomas).
Significant differences are evident between this lymphoma and the plasmacytoma model. 3 First, C57BL6 mice are resistant to plasmacytoma development. Previous studies have shown that a peritoneal inflammatory response with granuloma formation does occur in these mice, however. Second, pristane-induced plasmacytomas secrete IgA, whereas the lymphomas in our model express RNA for Cm and surface IgM. Third, pristane-induced plasmacytomas occur when young mice are injected and have a latency of about 1 year, whereas the lymphoma in our model occurs only when older mice are injected and then has a short latency period.
The age dependence makes this model somewhat cumbersome as a model in which to test new therapeutic approaches. Nonetheless, we have established a cell line derived from one of these lymphomas, which will prove useful for therapeutic testing. It is more likely that this multistep model will aid in developing a more complete understanding of the required steps in mantle cell lymphomagenesis and thus indicate potential new targets for therapy.
